Filing Flows › Bioadaptives (BDPT) › Q1 2026 › vs Q4 2025
Bioadaptives (BDPT) Q1 2026 vs Q4 2025 (quarter over quarter)
Bioadaptives's revenue fell $5K (-47%) from $10K in Q4 2025 to $6K in Q1 2026.
Bioadaptives, Q1 2026: revenue $6K, net loss $111K, operating cash flow −$85K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $6K | $10K | −$5K | -47% |
| Other income, net | $87K | −$575K | $662K | — |
| Net loss | $111K | $823K | −$712K | -87% |
| Costs & expenses | $204K | $834K | −$630K | -76% |
| Operating costs | $204K | $259K | −$55K | -21% |
| Cost of revenue | $1K | $3K | −$1K | -51% |
| General & admin | $181K | $228K | −$47K | -21% |
| Other operating costs | $21K | $27K | −$6K | -22% |
| Operating cash sources | $111K | $823K | −$712K | -87% |
| Depreciation & amortization | $2K | $2K | $0 | 0% |
| Working capital & other | $25K | $666K | −$641K | -96% |
| Cash used in operations | $85K | $156K | −$71K | -46% |
| Net loss absorbed | $111K | $823K | −$712K | -87% |
Questions
How much did Bioadaptives's revenue grow quarter over quarter in Q1 2026?
Bioadaptives's revenue fell $5K (-47%) from $10K in Q4 2025 to $6K in Q1 2026.